In the diabetic retina, SME treatment attenuated CML formation, the CML–RAGE interaction, and activation of the pro-inflammatory responses (VEGF, GFAP, S100B, and RAGE). The gene discussed is GFAP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.